Melbourn Scientific has announced a fast formulation-screening service that is aimed at accelerating the development of formulations where poor bioavailability is an issue.
The service includes investment in a new platform technology that will allow analysts to rapidly evaluate a range of formulations.
This extension to its formulation capability, which includes Good Manufacturing Practice (GMP) of capsules for early-phase clinical trials, is focused on making drug and device development programmes faster and more productive.
Mark Hammond, chief executive officer for Melbourn Scientific, said that in the early stages the concept of fit-for-purpose is paramount to an efficient transition from lead optimisation to first-in-man studies.
He said: 'An experienced partner will ensure that the formulation and testing procedures reflect the adequate requirements for a pre-clinical or first-in-man trial while making certain that sufficient data is collated for regulatory purposes at each stage.
'This will help the product get to clinic in a cost-effective and time-efficient manner,' he added.
Melbourn Scientific has a large team of analysts, formulators and product development experts.
Other facilities include a formulation suite with lab-scale manufacture, support for novel device development, and extended stability storage and test rooms.
